About us

Jean-Paul Renaud

President & CSO and acting CEO, cofounder.

Jean-Paul Renaud created the company in October 2015. He was previously CSO Science & Technology at NovAliX, an innovative drug discovery CRO (2010-2014) ; President & CEO-CSO of AliX (2002-2008), another spinoff company from IGBMC he created in 2002 (AliX’ merger with Novalyst Discovery gave birth to NovAliX in 2009) ; CNRS Research Director at IGBMC (2000-2002, 2008-2009 and 2014-2015) ; CNRS Research Associate at IGBMC (1993-2000) and previously at LCBPT (1988-1993). He was a post-doc at the MRC Laboratory of Molecular Biology in Cambridge, UK (1987-1988) under the mentoring of Kiyoshi Nagai. He obtained his PhD in Organic Chemistry from University Pierre & Marie Curie (Paris 6) in 1986 (Eugène Schueller Prize 1986) and an Engineering Diploma from the École Nationale Supérieure de Chimie de Paris (now Chimie ParisTech) in 1982. Jean-Paul Renaud was twice laureate of the french iLAB Contest (Concours national d’aide à la création d’entreprises de technologie innovantes) in the Creation – Development category : in 2002 for AliX and in 2017 for Urania Therapeutics, formerly called RiboStruct. He was also laureate of Réseau Entreprendre Alsace in 2006 for AliX.



In collaboration with the Yusupov lab at IGBMC, Urania publishes today an article in Nature entitled "Accuracy mechanism of eukaryotic ribosome translocation" describing the 3.2-Å-resolution X-ray structure of the eukaryotic 80S ribosome in a translocation-intermediate state containing mRNA, the elongation factor eEF2 and tRNAs. The model demonstrates how the decoding centre releases a codon–anticodon duplex, allowing its movement on the ribosome. This experimental structure suggests how the 80S ribosome, eEF2 and tRNAs undergo large-scale molecular reorganizations to ensure maintenance of the mRNA reading frame during the complex process of translocation.

This article demonstrates Urania's scientists' capacity to solve high-resolution structures of eukaryotic ribosome complex, to understand at the molecular level the mechanism of the eukaryotic ribosome and to make use of this knowledge to design using a structure-based approach new drug candidates modulating the human ribosome.

This website uses cookies to improve user experience